Ct-p44 Jun 2026

is an investigational subcutaneous biosimilar to the blockbuster drug Darzalex® (daratumumab) , currently being developed by South Korean biopharmaceutical giant Celltrion . As a targeted monoclonal antibody, CT-P44 is designed to treat multiple myeloma , a type of blood cancer that develops in plasma cells within the bone marrow. Therapeutic Overview: What is CT-P44?

Preclinical studies have demonstrated the efficacy and safety of CT-P44 in various tumor models. In a study published in the Journal of Clinical Oncology, researchers showed that CT-P44: ct-p44

| Parameter | Specification | | :--- | :--- | | | CT-P44 | | Input Voltage | 100-240 VAC, 50/60 Hz | | Output Voltage | 48 VDC (Adjustable 42-58V) | | Max Current | 90A | | Efficiency | ≥ 94% | | Cooling Method | Forced Air (Smart Fan) | | Dimensions | 450mm x 220mm x 150mm | | Weight | 7.2 kg (15.8 lbs) | | Operating Temp | -20°C to +50°C | ct-p44